EVE (NYSE:EVEX – Get Free Report)‘s stock had its “overweight” rating reissued by equities researchers at Cantor Fitzgerald in a report released on Monday, Benzinga reports. They presently have a $5.00 price target on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 59.24% from the company’s previous close.
Several other brokerages have also weighed in on EVEX. HC Wainwright began coverage on EVE in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $6.00 target price on the stock. Canaccord Genuity Group lowered their price target on EVE from $9.00 to $8.50 and set a “buy” rating on the stock in a report on Tuesday, July 2nd.
Get Our Latest Analysis on EVEX
EVE Price Performance
EVE (NYSE:EVEX – Get Free Report) last issued its earnings results on Tuesday, August 6th. The company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). On average, research analysts expect that EVE will post -0.49 EPS for the current year.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in EVE stock. Vanguard Group Inc. boosted its holdings in Eve Holding, Inc. (NYSE:EVEX – Free Report) by 7.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 517,707 shares of the company’s stock after acquiring an additional 34,484 shares during the quarter. Vanguard Group Inc. owned about 0.19% of EVE worth $2,796,000 as of its most recent SEC filing. 1.27% of the stock is currently owned by institutional investors and hedge funds.
About EVE
Eve Holding, Inc, together with its subsidiaries, develops urban air mobility solutions. It is involved in the design and production of electrical vertical take-off and landing vehicles (eVTOLs); provision of eVTOL service and support capabilities, including material services, maintenance, technical support, training, ground handling, and data services; and development of urban air traffic management systems.
Further Reading
- Five stocks we like better than EVE
- What to Know About Investing in Penny Stocks
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- 3 REITs to Buy and Hold for the Long Term
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Pros And Cons Of Monthly Dividend Stocks
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for EVE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EVE and related companies with MarketBeat.com's FREE daily email newsletter.